pCDCAR1 CSPG4 h(BBζ)(CAR-MZ200)
The vector of anti-CSPG4 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CSPG4. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-CSPG4 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of CSPG4-positive solid tumors including melanoma, breast carcinoma, HNSCC and mesothelioma.
Targeting Cell Type
CSPG4-positive solid tumors including melanoma, breast carcinoma, HNSCC and mesothelioma
Discription of Signaling Cassetes
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
chondroitin sulfate proteoglycan 4
CSPG4; chondroitin sulfate proteoglycan 4; NG2; MCSP; MCSPG; MSK16; HMW-MAA; MEL-CSPG; chondroitin sulfate proteoglycan NG2; melanoma chondroitin sulfate proteoglycan; melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteoglycan 4 (melanoma-associated); anti-HMW-MAA
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CSPG4 (763.74) h(CD3ζ) CAR, pCDCAR1
||Anti-HMW-MAA scFv h(CD4-FcεRIγ) CART, pCDCAR1
||Anti-CSPG4 (TP41.2) h(CD28-CD3ζ) CAR, pCDCAR1
||Anti-HMW-MAA scFv h(CD28) CART, pCDCAR1
||Anti-CSPG4 (763.74) h(CD28-CD3ζ) CAR, pCDCAR1
||Anti-HMW-MAA scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(CD8-CD3ζ) CART, pCDCAR1
||Anti-CSPG4 (G71.1) h(CD28-CD3ζ) CAR, pCDCAR1
||Anti-HMW-MAA scFv h(41BB-CD3ζ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(b2c-CD3ζ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(CD4-CD3ζ) CART, pCDCAR1
||Anti-CSPG4 (149.53) h(CD28-CD3ζ) CAR, pCDCAR1
||Anti-HMW-MAA scFv h(FcεRIγ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(CD3ζ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(CD28-FcεRIγ) CART, pCDCAR1
||Anti-HMW-MAA scFv h(CD28-CD3ζ) CART, pCDCAR1